Deciphera Pharmaceuticals (NASDAQ:DCPH) had its price target dropped by stock analysts at Canaccord Genuity from $55.00 to $50.00 in a note issued to investors on Friday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s target price suggests a potential upside of 93.69% from the company’s current price.
Several other equities research analysts also recently weighed in on DCPH. Leerink Swann lowered their target price on shares of Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating for the company in a research note on Friday, November 16th. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 target price on shares of Deciphera Pharmaceuticals in a research note on Thursday, December 20th. B. Riley initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, December 31st. They issued a “buy” rating and a $34.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Tuesday, January 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. Deciphera Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $42.11.
DCPH traded up $0.32 during trading on Friday, hitting $25.82. The stock had a trading volume of 90,014 shares, compared to its average volume of 201,945. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.63 and a beta of 3.27. Deciphera Pharmaceuticals has a twelve month low of $18.55 and a twelve month high of $45.61. The company has a quick ratio of 18.46, a current ratio of 18.46 and a debt-to-equity ratio of 0.06.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Thursday, March 14th. The company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.13). On average, sell-side analysts expect that Deciphera Pharmaceuticals will post -2.59 EPS for the current year.
In other Deciphera Pharmaceuticals news, insider Michael Douglas Taylor sold 9,431 shares of the firm’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $28.85, for a total value of $272,084.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Thomas Patrick Kelly sold 5,000 shares of the firm’s stock in a transaction on Monday, January 7th. The stock was sold at an average price of $25.18, for a total transaction of $125,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 198,426 shares of company stock valued at $5,247,846. Corporate insiders own 20.61% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of DCPH. Great West Life Assurance Co. Can purchased a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth $50,000. Legal & General Group Plc raised its holdings in shares of Deciphera Pharmaceuticals by 55.4% during the third quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after purchasing an additional 587 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Deciphera Pharmaceuticals by 316.1% during the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after purchasing an additional 1,982 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter worth $235,000. Finally, Rhumbline Advisers raised its holdings in shares of Deciphera Pharmaceuticals by 53.6% during the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after purchasing an additional 4,000 shares during the last quarter. 57.28% of the stock is owned by institutional investors and hedge funds.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Further Reading: Why is cost of goods sold important?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.